Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has completed the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009.

Arrowhead Research Corporation (NASDAQ: ARWR) announced today that the Company's CEO has provided an update letter to stockholders on its majority owned subsidiary, Calando Pharmaceuticals: Dear Arrowhead Stockholders, Calando Pharmaceuticals is Arrowhead's most mature biopharmaceutical subsidiary.

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has announced that preclinical development of a second siRNA oncology therapeutic, CALAA-02, is underway.

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has announced that the first patient has successfully completed the first dosing cycle of CALAA-01 in the first clinical trial using systemically-delivered siRNA to treat cancer.

Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research, has received FDA approval for its investigational new drug application for lead anti-cancer compound, CALAA-01.